‘Living Well With a PICC at Home’: Co‐Design and Evaluation of a Peripherally Inserted Central Catheter (PICC) Booklet

ABSTRACT

Aim

To co-design an information booklet to support adults living with a peripherally inserted central catheter (PICC) at home.

Design

A sequential, mixed-method approach using Boyd's co-design framework.

Method

A diverse project team led co-design of a PICC booklet based on preferences and PICC management strategies identified through content analysis of interviews with 15 Australian health consumers (January 2022–March 2023) using a qualitative descriptive approach. A draft booklet was developed, reviewed by the team and prototyped, which was evaluated by consumer participants and an external nurse panel, with readability assessed using Flesch Reading Ease and Flesch–Kincaid scores. The project team reviewed feedback, reached consensus on changes and collaborated with designers to produce the final booklet.

Results

Consumer participant strategies were classified into four categories: enhancing coping, taking responsibility and understanding information, modifying life and accessing supports. Two pre-determined categories were included (participant recommendations for PICC education resource content and top tips for living with a PICC). The prototype was evaluated as highly relevant (3.9/4), comprehensive (3.8/4) with an appropriate writing style and visual appeal. Readability scores were 76.1/100 (Flesch Reading Ease) and 6.9 (Flesch–Kincaid grade level). The final booklet contained 13 sections.

Conclusion

A co-design approach successfully created a novel PICC information booklet with positive evaluations.

Implications

Provides understanding of consumer information preferences to inform PICC education and offers insight into consumer-developed strategies and knowledge for living with a PICC.

Impact

A co-designed PICC information booklet based on consumer knowledge may augment nursing education for people living with a PICC to improve outcomes.

Reporting Method

The qualitative component follows the EQUATOR network COREQ guideline. A co-design research reporting standard is not available.

Patient or Public Contribution

A consumer representative was a member of the project team and contributed to study design, interpretation of findings and development of the booklet and manuscript.

Association between aspartate aminotransferase to alanine aminotransferase ratio and 28-day mortality of ICU patients: A retrospective cohort study from MIMIC-IV database

by Yanping Wang, Yan Xu

Background

Prior studies have linked the aspartate aminotransferase to alanine aminotransferase ratio (AAR) with negative health outcomes in the elderly and specific populations. However, the impact of AAR on the prognosis of the entire population in the intensive care unit (ICU) remains unclear. This study aimed to determine the correlation between AAR and the mortality among adult ICU patients.

Method

Patient data were retrieved from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database and stratified into quartiles by AAR. Survival analysis using the Kaplan-Meier curves was conducted to compare survival across quartiles. The primary outcome was 28-day mortality, with secondary outcomes including 60-day, 90-day, and 365-day mortality, along with ICU-free, ventilator-free, and vasopressor-free days within the first 28 days. The association between AAR and mortality was evaluated using Cox proportional hazards regression analysis complemented by a restricted cubic spline. Furthermore, the eICU Collaborative Research Database (eICU-CRD) was used as an external validation cohort for sensitivity analysis.

Result

The study included 20,225 patients with a mean age of 63.7 ± 17.5 years. Kaplan-Meier analysis indicated a higher risk of 28-day mortality for patients with higher AAR (log-rank P  Conclusion

AAR demonstrated a significant association with 28-day, 60-day, 90-day, and 365-day mortality, characterized by an inverted L-shaped pattern.

The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice

by Mayuko Takezaki, Biaoru Li, Hongyan Xu, Nikhil Patel, Rudolf Lucas, Ryan E. Cerbone, Sivanagireddy Koti, Clifford L. Hendrick, Louis H. Junker, Betty S. Pace

The most common hemoglobin disorder worldwide is sickle cell disease (SCD) caused by a point mutation in the adult β-globin gene. As a result, hemoglobin S production occurs leading to clinical symptoms including vaso-occlusive pain, organ damage, and a shortened lifespan. Hydroxyurea is the only FDA-approved fetal hemoglobin (HbF) inducer in the United States that ameliorates the clinical severity of SCD. Due to challenges with hydroxyurea, our study aimed to address the unmet need for the development of non-chemotherapeutic HbF inducers. We investigated the ability of CT-101, a Class 1 histone deacetylase inhibitor, to flip the γ-globin to β-globin switch in a humanized SCD mouse model. Pharmacokinetic parameters were assessed in CD-1 and Townes SCD mice after a single intraperitoneal drug dose. Similar drug uptake and half-life were observed in both animals. Subsequent studies in β-YAC mice expressing human γ-globin and β-globin genes established the optimal dose of CT-101 that induces HbF without peripheral blood toxicity. Subsequent confirmatory studies were conducted in the SCD mouse treated with intraperitoneal CT-101, demonstrating increases in F-cells, HbF, and γ-globin gene mRNA levels. Hydroxyurea combined with CT-101 significantly decreased spleen size and hemorrhagic infarcts and improved splenic extramedullary hematopoiesis. Our novel agent, CT-101, flipped the switch by activating γ-globin gene transcription and HbF protein synthesis in the preclinical SCD mouse model without significant toxicity in the peripheral blood. These findings support the development of an oral CT-101 formulation for clinical testing in SCD.

Impact of prophylactic wound closure in colorectal ESD on postoperative wound complications: A meta‐analysis

Abstract

Endoscopic submucosa dissection (ESD) has been applied extensively in the treatment of large intestine tumours due to its high total excision ratio. Nevertheless, there is a high incidence of adverse reactions in colon ESD, and the efficacy of prophylactic ESD following ESD in prevention of postoperative haemorrhage is still disputed. The purpose of this meta-analysis is to evaluate the effectiveness of prophylaxis of wound closure in large intestine ESD after operation. For eligibility, we looked through three databases: PubMed, Embase and Cochrane Library. Heterogenity was measured by means of a chi-square method of Q-statistic and an I2 test. Fixed or random effects models were used for data processing. Based on the retrieval policy, we found a total of 1286 papers, and then we collected nine papers to extract the data. Regarding postoperative haemorrhage, there was a significant reduction in the risk of wound haemorrhage in the wound closure group than in the control group (OR, 0.29; 95% CI, 0.19–0.44 p < 0.0001). No statistical significance was found in the incidence of perforation in the wound closure and the control group (OR, 0.45; 95% CI, 0.19–1.03 p = 0.06). There was a significant reduction in the incidence of postoperation fever among those in the wound closure group than in the control group (OR, 0.37; 95% CI, 0.15–0.93 p = 0.04). Preventive endoscopic closure decreased the rate of ESD in colon disease, but did not significantly decrease the rate of postoperation perforation and postoperative fever. Future research will be required to clarify the risk factors and classify high-risk individuals in order to formulate a cost-effective prevention strategy.